Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2017 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for any statement in the transcript that indicates an escalation in the size of individual deals, orders, contracts, etc., compared to the company's own past. The transcript is from Dana Inc.'s Q1 2017 earnings call. Management discusses acquisitions, new programs, market conditions, etc. Key points: They mention acquisitions (Brevini, USM, SIFCO, Magnum) but those are acquisitions, not orders or contracts. They talk about new vehicle programs like Ford Super Duty, Jeep Wrangler, Toyota HiLux. They talk about market conditions. They talk about revenue growth, organic growth, etc. But the question is specifically about the size of individual engagements (deals, orders, contracts, projects, customers, sites, programs) escalating. For example, are they saying that the average size of new orders is larger than before? Or that new customers are starting at a larger scale? Or that follow-on commitments are larger? Looking through the transcript, I see no such statement. Management talks about growth in revenue, organic growth, new business, but not about the individual size of deals increasing. They mention "new business" and "backlog" but not that each new order is bigger. They talk about acquisitions adding sales, but that's not the same as organic deal size escalation. They mention "we are well under way with the integration of the new Warren, Michigan facility" and "we are well on our way with our Brevini integration synergy plan" but that's about acquisitions. They talk about "new vehicle programs completing their planned launch acceleration, reaching full volume run rates" - that's about volume, not necessarily larger individual deals. They talk about "improved end market demand" - that's market conditions. They talk about "incremental sales associated with Dana's recently completed M&A actions" - again, acquisitions.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.